Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 24 entries
Sorted by: Best Match Show Resources per page
Liver fibrosis and CD206.

JHEP reports : innovation in hepatology

Tan-Garcia A, Lai F, Sheng Yeong JP, Irac SE, Ng PY, Msallam R, Tatt Lim JC, Wai LE, Tham CYL, Choo SP, Lim T, Young DY, D'Ambrosio R, Degasperi E, Perbellini R, Newell E, Le Bert N, Ginhoux F, Bertoletti A, Chen Q, Dutertre CA.
PMID: 32039403
JHEP Rep. 2019 Dec 06;2(1):100062. doi: 10.1016/j.jhepr.2019.11.006. eCollection 2020 Feb.

BACKGROUND & AIMS: Chronic liver inflammation leads to fibrosis and cirrhosis and is associated with an accumulation of intrahepatic TNFα-secreting CD206METHODS: Liver immunohistochemistry and serum quantification were performed in patients with viral and non-viral-related liver disease to compare CD206RESULTS:...

Cite
Tan-Garcia A, Lai F, Sheng Yeong JP, et al. Liver fibrosis and CD206. JHEP Rep. 2019;2(1):100062doi: 10.1016/j.jhepr.2019.11.006.
Tan-Garcia, A., Lai, F., Sheng Yeong, J. P., Irac, S. E., Ng, P. Y., Msallam, R., Tatt Lim, J. C., Wai, L. E., Tham, C. Y. L., Choo, S. P., Lim, T., Young, D. Y., D'Ambrosio, R., Degasperi, E., Perbellini, R., Newell, E., Le Bert, N., Ginhoux, F., Bertoletti, A., Chen, Q., & Dutertre, C. A. (2020). Liver fibrosis and CD206. JHEP reports : innovation in hepatology, 2(1), 100062. https://doi.org/10.1016/j.jhepr.2019.11.006
Tan-Garcia, Alfonso, et al. "Liver fibrosis and CD206." JHEP reports : innovation in hepatology vol. 2,1 (2020): 100062. doi: https://doi.org/10.1016/j.jhepr.2019.11.006
Tan-Garcia A, Lai F, Sheng Yeong JP, Irac SE, Ng PY, Msallam R, Tatt Lim JC, Wai LE, Tham CYL, Choo SP, Lim T, Young DY, D'Ambrosio R, Degasperi E, Perbellini R, Newell E, Le Bert N, Ginhoux F, Bertoletti A, Chen Q, Dutertre CA. Liver fibrosis and CD206. JHEP Rep. 2019 Dec 06;2(1):100062. doi: 10.1016/j.jhepr.2019.11.006. eCollection 2020 Feb. PMID: 32039403; PMCID: PMC7005658.
Copy Download .nbib Format: NLM
Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells.

Journal for immunotherapy of cancer

Dalla Pietà A, Cappuzzello E, Palmerini P, Ventura A, Visentin A, Astori G, Chieregato K, Mozzo V, Perbellini O, Tisi MC, Trentin L, Visco C, Ruggeri M, Sommaggio R, Rosato A.
PMID: 34272306
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-002475.

BACKGROUND: Patients affected by aggressive B-cell malignancies who are resistant to primary or salvage chemoimmunotherapy have an extremely poor prognosis and limited therapeutic options. Promising therapeutic success has been achieved with the infusion of CD19 chimeric antigen receptor-T cells,...

Cite
Dalla Pietà A, Cappuzzello E, Palmerini P, et al. Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. J Immunother Cancer. 2021;9(7)doi: 10.1136/jitc-2021-002475.
Dalla Pietà, A., Cappuzzello, E., Palmerini, P., Ventura, A., Visentin, A., Astori, G., Chieregato, K., Mozzo, V., Perbellini, O., Tisi, M. C., Trentin, L., Visco, C., Ruggeri, M., Sommaggio, R., & Rosato, A. (2021). Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. Journal for immunotherapy of cancer, 9(7), . https://doi.org/10.1136/jitc-2021-002475
Dalla Pietà, Anna, et al. "Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells." Journal for immunotherapy of cancer vol. 9,7 (2021). doi: https://doi.org/10.1136/jitc-2021-002475
Dalla Pietà A, Cappuzzello E, Palmerini P, Ventura A, Visentin A, Astori G, Chieregato K, Mozzo V, Perbellini O, Tisi MC, Trentin L, Visco C, Ruggeri M, Sommaggio R, Rosato A. Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-002475. PMID: 34272306; PMCID: PMC8287629.
Copy Download .nbib Format: NLM
Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents.

Alimentary pharmacology & therapeutics

Degasperi E, Perbellini R, D'Ambrosio R, Uceda Renteria SC, Ceriotti F, Perego A, Orsini C, Borghi M, Iavarone M, Bruccoleri M, Rimondi A, De Silvestri A, Sangiovanni A, Lampertico P.
PMID: 34738664
Aliment Pharmacol Ther. 2022 Feb;55(3):350-359. doi: 10.1111/apt.16685. Epub 2021 Nov 05.

BACKGROUND: Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) and alpha fetoprotein (AFP) are biomarkers for hepatocellular carcinoma (HCC). However, their performance in patients with cirrhosis related to hepatitis C virus (HCV) treated with direct-acting antiviral agents (DAA)...

Cite
Degasperi E, Perbellini R, D'Ambrosio R, et al. Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. Aliment Pharmacol Ther. 2021;55(3):350-359doi: 10.1111/apt.16685.
Degasperi, E., Perbellini, R., D'Ambrosio, R., Uceda Renteria, S. C., Ceriotti, F., Perego, A., Orsini, C., Borghi, M., Iavarone, M., Bruccoleri, M., Rimondi, A., De Silvestri, A., Sangiovanni, A., & Lampertico, P. (2022). Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. Alimentary pharmacology & therapeutics, 55(3), 350-359. https://doi.org/10.1111/apt.16685
Degasperi, Elisabetta, et al. "Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents." Alimentary pharmacology & therapeutics vol. 55,3 (2022): 350-359. doi: https://doi.org/10.1111/apt.16685
Degasperi E, Perbellini R, D'Ambrosio R, Uceda Renteria SC, Ceriotti F, Perego A, Orsini C, Borghi M, Iavarone M, Bruccoleri M, Rimondi A, De Silvestri A, Sangiovanni A, Lampertico P. Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. Aliment Pharmacol Ther. 2022 Feb;55(3):350-359. doi: 10.1111/apt.16685. Epub 2021 Nov 05. PMID: 34738664.
Copy Download .nbib Format: NLM
Uppermost crustal structure regulates the flow of the Greenland Ice Sheet.

Nature communications

Jones GA, Ferreira AMG, Kulessa B, Schimmel M, Berbellini A, Morelli A.
PMID: 34911961
Nat Commun. 2021 Dec 15;12(1):7307. doi: 10.1038/s41467-021-27537-5.

The flow of the Greenland Ice Sheet is controlled by subglacial processes and conditions that depend on the geological provenance and temperature of the crust beneath it, neither of which are adequately known. Here we present a seismic velocity...

Cite
Jones GA, Ferreira AMG, Kulessa B, et al. Uppermost crustal structure regulates the flow of the Greenland Ice Sheet. Nat Commun. 2021;12(1):7307doi: 10.1038/s41467-021-27537-5.
Jones, G. A., Ferreira, A. M. G., Kulessa, B., Schimmel, M., Berbellini, A., & Morelli, A. (2021). Uppermost crustal structure regulates the flow of the Greenland Ice Sheet. Nature communications, 12(1), 7307. https://doi.org/10.1038/s41467-021-27537-5
Jones, G A, et al. "Uppermost crustal structure regulates the flow of the Greenland Ice Sheet." Nature communications vol. 12,1 (2021): 7307. doi: https://doi.org/10.1038/s41467-021-27537-5
Jones GA, Ferreira AMG, Kulessa B, Schimmel M, Berbellini A, Morelli A. Uppermost crustal structure regulates the flow of the Greenland Ice Sheet. Nat Commun. 2021 Dec 15;12(1):7307. doi: 10.1038/s41467-021-27537-5. PMID: 34911961; PMCID: PMC8674248.
Copy Download .nbib Format: NLM
New process for production of fermented black table olives using selected autochthonous microbial resources.

Frontiers in microbiology

Tufariello M, Durante M, Ramires FA, Grieco F, Tommasi L, Perbellini E, Falco V, Tasioula-Margari M, Logrieco AF, Mita G, Bleve G.
PMID: 26441932
Front Microbiol. 2015 Sep 24;6:1007. doi: 10.3389/fmicb.2015.01007. eCollection 2015.

Table olives represent one important fermented product in Europe and, in the world, their demand is constantly increasing. At the present time, no systems are available to control black table olives spontaneous fermentation by the Greek method. During this...

Cite
Tufariello M, Durante M, Ramires FA, et al. New process for production of fermented black table olives using selected autochthonous microbial resources. Front Microbiol. 2015;6:1007doi: 10.3389/fmicb.2015.01007.
Tufariello, M., Durante, M., Ramires, F. A., Grieco, F., Tommasi, L., Perbellini, E., Falco, V., Tasioula-Margari, M., Logrieco, A. F., Mita, G., & Bleve, G. (2015). New process for production of fermented black table olives using selected autochthonous microbial resources. Frontiers in microbiology, 61007. https://doi.org/10.3389/fmicb.2015.01007
Tufariello, Maria, et al. "New process for production of fermented black table olives using selected autochthonous microbial resources." Frontiers in microbiology vol. 6 (2015): 1007. doi: https://doi.org/10.3389/fmicb.2015.01007
Tufariello M, Durante M, Ramires FA, Grieco F, Tommasi L, Perbellini E, Falco V, Tasioula-Margari M, Logrieco AF, Mita G, Bleve G. New process for production of fermented black table olives using selected autochthonous microbial resources. Front Microbiol. 2015 Sep 24;6:1007. doi: 10.3389/fmicb.2015.01007. eCollection 2015. PMID: 26441932; PMCID: PMC4585182.
Copy Download .nbib Format: NLM
Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.

Journal of hepatology

Loglio A, Ferenci P, Uceda Renteria SC, Tham CYL, Scholtes C, Holzmann H, van Bömmel F, Borghi M, Perbellini R, Rimondi A, Farina E, Trombetta E, Manunta M, Porretti L, Prati D, Ceriotti F, Zoulim F, Bertoletti A, Lampertico P.
PMID: 34699951
J Hepatol. 2021 Oct 23; doi: 10.1016/j.jhep.2021.10.012. Epub 2021 Oct 23.

The entry inhibitor bulevirtide (BLV) received conditional approval from the EMA in July 2020 for the treatment of adult patients with compensated chronic hepatitis delta. However, the effectiveness and safety of BLV administered as monotherapy beyond 48 weeks in...

Cite
Loglio A, Ferenci P, Uceda Renteria SC, et al. Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. J Hepatol. 2021;doi: 10.1016/j.jhep.2021.10.012.
Loglio, A., Ferenci, P., Uceda Renteria, S. C., Tham, C. Y. L., Scholtes, C., Holzmann, H., van Bömmel, F., Borghi, M., Perbellini, R., Rimondi, A., Farina, E., Trombetta, E., Manunta, M., Porretti, L., Prati, D., Ceriotti, F., Zoulim, F., Bertoletti, A., & Lampertico, P. (2021). Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. Journal of hepatology, . https://doi.org/10.1016/j.jhep.2021.10.012
Loglio, Alessandro, et al. "Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis." Journal of hepatology vol. (2021). doi: https://doi.org/10.1016/j.jhep.2021.10.012
Loglio A, Ferenci P, Uceda Renteria SC, Tham CYL, Scholtes C, Holzmann H, van Bömmel F, Borghi M, Perbellini R, Rimondi A, Farina E, Trombetta E, Manunta M, Porretti L, Prati D, Ceriotti F, Zoulim F, Bertoletti A, Lampertico P. Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. J Hepatol. 2021 Oct 23; doi: 10.1016/j.jhep.2021.10.012. Epub 2021 Oct 23. PMID: 34699951.
Copy Download .nbib Format: NLM
Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents.

Alimentary pharmacology & therapeutics

Degasperi E, Perbellini R, D'Ambrosio R, Uceda Renteria SC, Ceriotti F, Perego A, Orsini C, Borghi M, Iavarone M, Bruccoleri M, Rimondi A, De Silvestri A, Sangiovanni A, Lampertico P.
PMID: 34738664
Aliment Pharmacol Ther. 2021 Nov 05; doi: 10.1111/apt.16685. Epub 2021 Nov 05.

BACKGROUND: Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) and alpha fetoprotein (AFP) are biomarkers for hepatocellular carcinoma (HCC). However, their performance in patients with cirrhosis related to hepatitis C virus (HCV) treated with direct-acting antiviral agents (DAA)...

Cite
Degasperi E, Perbellini R, D'Ambrosio R, et al. Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. Aliment Pharmacol Ther. 2021;doi: 10.1111/apt.16685.
Degasperi, E., Perbellini, R., D'Ambrosio, R., Uceda Renteria, S. C., Ceriotti, F., Perego, A., Orsini, C., Borghi, M., Iavarone, M., Bruccoleri, M., Rimondi, A., De Silvestri, A., Sangiovanni, A., & Lampertico, P. (2021). Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. Alimentary pharmacology & therapeutics, . https://doi.org/10.1111/apt.16685
Degasperi, Elisabetta, et al. "Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents." Alimentary pharmacology & therapeutics vol. (2021). doi: https://doi.org/10.1111/apt.16685
Degasperi E, Perbellini R, D'Ambrosio R, Uceda Renteria SC, Ceriotti F, Perego A, Orsini C, Borghi M, Iavarone M, Bruccoleri M, Rimondi A, De Silvestri A, Sangiovanni A, Lampertico P. Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. Aliment Pharmacol Ther. 2021 Nov 05; doi: 10.1111/apt.16685. Epub 2021 Nov 05. PMID: 34738664.
Copy Download .nbib Format: NLM
A flow cytometric assay for the quantification of MSC lysis by peripheral blood mononucleated cells.

Heliyon

Chieregato K, Bernardi M, Alghisi A, Giordano R, Lazzari L, Perbellini O, Rassu M, Ruggeri M, Astori G.
PMID: 33553772
Heliyon. 2021 Feb 01;7(2):e06036. doi: 10.1016/j.heliyon.2021.e06036. eCollection 2021 Feb.

Mesenchymal stromal cells (MSC) are attractive candidates for the treatment of acute graft versus host disease (aGvHD) or autoimmune disorders. However, mechanisms of MSC recognition remain unclear and there are evidences that MSC are not totally immunoprivileged. Data suggest...

Cite
Chieregato K, Bernardi M, Alghisi A, et al. A flow cytometric assay for the quantification of MSC lysis by peripheral blood mononucleated cells. Heliyon. 2021;7(2):e06036doi: 10.1016/j.heliyon.2021.e06036.
Chieregato, K., Bernardi, M., Alghisi, A., Giordano, R., Lazzari, L., Perbellini, O., Rassu, M., Ruggeri, M., & Astori, G. (2021). A flow cytometric assay for the quantification of MSC lysis by peripheral blood mononucleated cells. Heliyon, 7(2), e06036. https://doi.org/10.1016/j.heliyon.2021.e06036
Chieregato, Katia, et al. "A flow cytometric assay for the quantification of MSC lysis by peripheral blood mononucleated cells." Heliyon vol. 7,2 (2021): e06036. doi: https://doi.org/10.1016/j.heliyon.2021.e06036
Chieregato K, Bernardi M, Alghisi A, Giordano R, Lazzari L, Perbellini O, Rassu M, Ruggeri M, Astori G. A flow cytometric assay for the quantification of MSC lysis by peripheral blood mononucleated cells. Heliyon. 2021 Feb 01;7(2):e06036. doi: 10.1016/j.heliyon.2021.e06036. eCollection 2021 Feb. PMID: 33553772; PMCID: PMC7856420.
Copy Download .nbib Format: NLM
Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart.

Cardiovascular research

van der Velden J, Asselbergs FW, Bakkers J, Batkai S, Bertrand L, Bezzina CR, Bot I, Brundel B, Carrier L, Chamuleau S, Ciccarelli M, Dawson D, Davidson SM, Dendorfer A, Duncker DJ, Eschenhagen T, Fabritz L, Falcão-Pires I, Ferdinandy P, Giacca M, Girao H, Gollmann-Tepeköylü C, Gyongyosi M, Guzik TJ, Hamdani N, Heymans S, Hilfiker A, Hilfiker-Kleiner D, Hoekstra AG, Hulot JS, Kuster DWD, van Laake LW, Lecour S, Leiner T, Linke WA, Lumens J, Lutgens E, Madonna R, Maegdefessel L, Mayr M, van der Meer P, Passier R, Perbellini F, Perrino C, Pesce M, Priori S, Remme CA, Rosenhahn B, Schotten U, Schulz R, Sipido K, Sluijter JPG, van Steenbeek F, Steffens S, Terracciano CM, Tocchetti CG, Vlasman P, Yeung KK, Zacchigna S, Zwaagman D, Thum T.
PMID: 34999816
Cardiovasc Res. 2022 Jan 06; doi: 10.1093/cvr/cvab370. Epub 2022 Jan 06.

Cardiovascular diseases represent a major cause of morbidity and mortality, necessitating research to improve diagnostics, and to discover and test novel preventive and curative therapies. All of which warrant experimental models that recapitulate human disease. The translation of basic...

Cite
van der Velden J, Asselbergs FW, Bakkers J, et al. Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart. Cardiovasc Res. 2022;doi: 10.1093/cvr/cvab370.
van der Velden, J., Asselbergs, F. W., Bakkers, J., Batkai, S., Bertrand, L., Bezzina, C. R., Bot, I., Brundel, B., Carrier, L., Chamuleau, S., Ciccarelli, M., Dawson, D., Davidson, S. M., Dendorfer, A., Duncker, D. J., Eschenhagen, T., Fabritz, L., Falcão-Pires, I., Ferdinandy, P., Giacca, M., Girao, H., Gollmann-Tepeköylü, C., Gyongyosi, M., Guzik, T. J., Hamdani, N., Heymans, S., Hilfiker, A., Hilfiker-Kleiner, D., Hoekstra, A. G., Hulot, J. S., Kuster, D. W. D., van Laake, L. W., Lecour, S., Leiner, T., Linke, W. A., Lumens, J., Lutgens, E., Madonna, R., Maegdefessel, L., Mayr, M., van der Meer, P., Passier, R., Perbellini, F., Perrino, C., Pesce, M., Priori, S., Remme, C. A., Rosenhahn, B., Schotten, U., Schulz, R., Sipido, K., Sluijter, J. P. G., van Steenbeek, F., Steffens, S., Terracciano, C. M., Tocchetti, C. G., Vlasman, P., Yeung, K. K., Zacchigna, S., Zwaagman, D., & Thum, T. (2022). Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart. Cardiovascular research, . https://doi.org/10.1093/cvr/cvab370
van der Velden, Jolanda, et al. "Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart." Cardiovascular research vol. (2022). doi: https://doi.org/10.1093/cvr/cvab370
van der Velden J, Asselbergs FW, Bakkers J, Batkai S, Bertrand L, Bezzina CR, Bot I, Brundel B, Carrier L, Chamuleau S, Ciccarelli M, Dawson D, Davidson SM, Dendorfer A, Duncker DJ, Eschenhagen T, Fabritz L, Falcão-Pires I, Ferdinandy P, Giacca M, Girao H, Gollmann-Tepeköylü C, Gyongyosi M, Guzik TJ, Hamdani N, Heymans S, Hilfiker A, Hilfiker-Kleiner D, Hoekstra AG, Hulot JS, Kuster DWD, van Laake LW, Lecour S, Leiner T, Linke WA, Lumens J, Lutgens E, Madonna R, Maegdefessel L, Mayr M, van der Meer P, Passier R, Perbellini F, Perrino C, Pesce M, Priori S, Remme CA, Rosenhahn B, Schotten U, Schulz R, Sipido K, Sluijter JPG, van Steenbeek F, Steffens S, Terracciano CM, Tocchetti CG, Vlasman P, Yeung KK, Zacchigna S, Zwaagman D, Thum T. Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart. Cardiovasc Res. 2022 Jan 06; doi: 10.1093/cvr/cvab370. Epub 2022 Jan 06. PMID: 34999816.
Copy Download .nbib Format: NLM
The CCR5 and CXCR3 Pathways in Hepatitis C Virus Liver Transplanted Recipients Treated by a Direct Antiviral Agent Regimen: Informative Kinetics Profiles.

Viral immunology

Colucci G, Invernizzi F, Uceda Renteria S, Perbellini R, Degasperi E, D'Ambrosio R, Galmozzi E, Lunghi G, Sguazzini E, Lampertico P, Donato MF.
PMID: 34252334
Viral Immunol. 2021 Oct;34(8):542-551. doi: 10.1089/vim.2021.0035. Epub 2021 Jul 12.

The CC5 and CXC3 chemokines (CK) pathways are involved in the pathogenesis and outcome of several disease states, including chronic hepatitis C (CHC). The kinetics of Regulated upon Activation Normal T cell Expressed and Secreted (RANTES) (CCL5) and IP-10...

Cite
Colucci G, Invernizzi F, Uceda Renteria S, et al. The CCR5 and CXCR3 Pathways in Hepatitis C Virus Liver Transplanted Recipients Treated by a Direct Antiviral Agent Regimen: Informative Kinetics Profiles. Viral Immunol. 2021;34(8):542-551doi: 10.1089/vim.2021.0035.
Colucci, G., Invernizzi, F., Uceda Renteria, S., Perbellini, R., Degasperi, E., D'Ambrosio, R., Galmozzi, E., Lunghi, G., Sguazzini, E., Lampertico, P., & Donato, M. F. (2021). The CCR5 and CXCR3 Pathways in Hepatitis C Virus Liver Transplanted Recipients Treated by a Direct Antiviral Agent Regimen: Informative Kinetics Profiles. Viral immunology, 34(8), 542-551. https://doi.org/10.1089/vim.2021.0035
Colucci, Giuseppe, et al. "The CCR5 and CXCR3 Pathways in Hepatitis C Virus Liver Transplanted Recipients Treated by a Direct Antiviral Agent Regimen: Informative Kinetics Profiles." Viral immunology vol. 34,8 (2021): 542-551. doi: https://doi.org/10.1089/vim.2021.0035
Colucci G, Invernizzi F, Uceda Renteria S, Perbellini R, Degasperi E, D'Ambrosio R, Galmozzi E, Lunghi G, Sguazzini E, Lampertico P, Donato MF. The CCR5 and CXCR3 Pathways in Hepatitis C Virus Liver Transplanted Recipients Treated by a Direct Antiviral Agent Regimen: Informative Kinetics Profiles. Viral Immunol. 2021 Oct;34(8):542-551. doi: 10.1089/vim.2021.0035. Epub 2021 Jul 12. PMID: 34252334.
Copy Download .nbib Format: NLM
Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.

Journal of hepatology

D'Ambrosio R, Degasperi E, Anolli MP, Fanetti I, Borghi M, Soffredini R, Iavarone M, Tosetti G, Perbellini R, Sangiovanni A, Sypsa V, Lampertico P.
PMID: 34592366
J Hepatol. 2021 Sep 27; doi: 10.1016/j.jhep.2021.09.013. Epub 2021 Sep 27.

BACKGROUND & AIMS: As the long-term benefits of a sustained virological response (SVR) in HCV-related cirrhosis following direct-acting antiviral (DAA) treatment remain undefined, we assessed the incidence and predictors of liver-related events (LREs), non-liver-related events (NLREs) and mortality in...

Cite
D'Ambrosio R, Degasperi E, Anolli MP, et al. Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol. 2021;doi: 10.1016/j.jhep.2021.09.013.
D'Ambrosio, R., Degasperi, E., Anolli, M. P., Fanetti, I., Borghi, M., Soffredini, R., Iavarone, M., Tosetti, G., Perbellini, R., Sangiovanni, A., Sypsa, V., & Lampertico, P. (2021). Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. Journal of hepatology, . https://doi.org/10.1016/j.jhep.2021.09.013
D'Ambrosio, Roberta, et al. "Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR." Journal of hepatology vol. (2021). doi: https://doi.org/10.1016/j.jhep.2021.09.013
D'Ambrosio R, Degasperi E, Anolli MP, Fanetti I, Borghi M, Soffredini R, Iavarone M, Tosetti G, Perbellini R, Sangiovanni A, Sypsa V, Lampertico P. Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol. 2021 Sep 27; doi: 10.1016/j.jhep.2021.09.013. Epub 2021 Sep 27. PMID: 34592366.
Copy Download .nbib Format: NLM
Heterocellularity and Cellular Cross-Talk in the Cardiovascular System.

Frontiers in cardiovascular medicine

Perbellini F, Watson SA, Bardi I, Terracciano CM.
PMID: 30443550
Front Cardiovasc Med. 2018 Nov 01;5:143. doi: 10.3389/fcvm.2018.00143. eCollection 2018.

Cellular specialization and interactions with other cell types are the essence of complex multicellular life. The orchestrated function of different cell populations in the heart, in combination with a complex network of intercellular circuits of communication, is essential to...

Cite
Perbellini F, Watson SA, Bardi I, et al. Heterocellularity and Cellular Cross-Talk in the Cardiovascular System. Front Cardiovasc Med. 2018;5:143doi: 10.3389/fcvm.2018.00143.
Perbellini, F., Watson, S. A., Bardi, I., & Terracciano, C. M. (2018). Heterocellularity and Cellular Cross-Talk in the Cardiovascular System. Frontiers in cardiovascular medicine, 5143. https://doi.org/10.3389/fcvm.2018.00143
Perbellini, Filippo, et al. "Heterocellularity and Cellular Cross-Talk in the Cardiovascular System." Frontiers in cardiovascular medicine vol. 5 (2018): 143. doi: https://doi.org/10.3389/fcvm.2018.00143
Perbellini F, Watson SA, Bardi I, Terracciano CM. Heterocellularity and Cellular Cross-Talk in the Cardiovascular System. Front Cardiovasc Med. 2018 Nov 01;5:143. doi: 10.3389/fcvm.2018.00143. eCollection 2018. PMID: 30443550; PMCID: PMC6221907.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 24 entries